Interlaboratory comparison of IDH mutation detection

Martin J. Van Den Bent, C. Hartmann, Matthias Preusser, Thomas Ströbel, Hendrikus J. Dubbink, Johan M. Kros, Andreas Von Deimling, Blandine Boisselier, Marc Sanson, Kevin C. Halling, Kristin L. Diefes, Kenneth Aldape, Caterina Giannini

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Isocitrate dehydrogenase (IDH) mutational testing is becoming increasingly important. For this, robust and reliable assays are needed. We tested the variation of results between six laboratories of testing for IDH mutations. Each laboratory received five unstained slides from 31 formalin-fixed paraffin-embedded (FFPE) glioma samples, and followed its own standard IDH diagnostic routine. All laboratories used immunohistochemistry (IHC) with an antibody against the most frequent IDH1 mutation (R132H) as a first step. Three laboratories then sequenced only IHC negative cases while the others sequenced all cases. Based on the overall analysis, 13 samples from 11 tumors had an R132H mutation and one tumor showed an R132G mutation. Results of IHC for IDH1 R132H mutations in all six laboratories were completely in agreement, and identified all R132H mutations. Upon sequencing the results of two laboratories deviated from those of the others. After a review of the entire diagnostic process, on repeat (blinded) testing one laboratory was completely in agreement with the overall result. A change in technique did only partially improve the results in the other laboratory. IHC for the IDH1 R132H mutation is very reliable and consistent across laboratories. IDH sequencing procedures yielded inconsistent results in 2 out of 6 laboratories. Quality assurance is pivotal before IDH testing is made part of clinical management of patients.

Original languageEnglish (US)
Pages (from-to)173-178
Number of pages6
JournalJournal of Neuro-Oncology
Volume112
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Isocitrate Dehydrogenase
Mutation
Immunohistochemistry
Glioma
Paraffin
Formaldehyde
Neoplasms

Keywords

  • IDH1
  • Immunohistochemistry
  • Interlaboratory comparison
  • Sequencing

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Van Den Bent, M. J., Hartmann, C., Preusser, M., Ströbel, T., Dubbink, H. J., Kros, J. M., ... Giannini, C. (2013). Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology, 112(2), 173-178. https://doi.org/10.1007/s11060-013-1056-z

Interlaboratory comparison of IDH mutation detection. / Van Den Bent, Martin J.; Hartmann, C.; Preusser, Matthias; Ströbel, Thomas; Dubbink, Hendrikus J.; Kros, Johan M.; Von Deimling, Andreas; Boisselier, Blandine; Sanson, Marc; Halling, Kevin C.; Diefes, Kristin L.; Aldape, Kenneth; Giannini, Caterina.

In: Journal of Neuro-Oncology, Vol. 112, No. 2, 04.2013, p. 173-178.

Research output: Contribution to journalArticle

Van Den Bent, MJ, Hartmann, C, Preusser, M, Ströbel, T, Dubbink, HJ, Kros, JM, Von Deimling, A, Boisselier, B, Sanson, M, Halling, KC, Diefes, KL, Aldape, K & Giannini, C 2013, 'Interlaboratory comparison of IDH mutation detection', Journal of Neuro-Oncology, vol. 112, no. 2, pp. 173-178. https://doi.org/10.1007/s11060-013-1056-z
Van Den Bent MJ, Hartmann C, Preusser M, Ströbel T, Dubbink HJ, Kros JM et al. Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology. 2013 Apr;112(2):173-178. https://doi.org/10.1007/s11060-013-1056-z
Van Den Bent, Martin J. ; Hartmann, C. ; Preusser, Matthias ; Ströbel, Thomas ; Dubbink, Hendrikus J. ; Kros, Johan M. ; Von Deimling, Andreas ; Boisselier, Blandine ; Sanson, Marc ; Halling, Kevin C. ; Diefes, Kristin L. ; Aldape, Kenneth ; Giannini, Caterina. / Interlaboratory comparison of IDH mutation detection. In: Journal of Neuro-Oncology. 2013 ; Vol. 112, No. 2. pp. 173-178.
@article{337858970c35469485a41fc894f364db,
title = "Interlaboratory comparison of IDH mutation detection",
abstract = "Isocitrate dehydrogenase (IDH) mutational testing is becoming increasingly important. For this, robust and reliable assays are needed. We tested the variation of results between six laboratories of testing for IDH mutations. Each laboratory received five unstained slides from 31 formalin-fixed paraffin-embedded (FFPE) glioma samples, and followed its own standard IDH diagnostic routine. All laboratories used immunohistochemistry (IHC) with an antibody against the most frequent IDH1 mutation (R132H) as a first step. Three laboratories then sequenced only IHC negative cases while the others sequenced all cases. Based on the overall analysis, 13 samples from 11 tumors had an R132H mutation and one tumor showed an R132G mutation. Results of IHC for IDH1 R132H mutations in all six laboratories were completely in agreement, and identified all R132H mutations. Upon sequencing the results of two laboratories deviated from those of the others. After a review of the entire diagnostic process, on repeat (blinded) testing one laboratory was completely in agreement with the overall result. A change in technique did only partially improve the results in the other laboratory. IHC for the IDH1 R132H mutation is very reliable and consistent across laboratories. IDH sequencing procedures yielded inconsistent results in 2 out of 6 laboratories. Quality assurance is pivotal before IDH testing is made part of clinical management of patients.",
keywords = "IDH1, Immunohistochemistry, Interlaboratory comparison, Sequencing",
author = "{Van Den Bent}, {Martin J.} and C. Hartmann and Matthias Preusser and Thomas Str{\"o}bel and Dubbink, {Hendrikus J.} and Kros, {Johan M.} and {Von Deimling}, Andreas and Blandine Boisselier and Marc Sanson and Halling, {Kevin C.} and Diefes, {Kristin L.} and Kenneth Aldape and Caterina Giannini",
year = "2013",
month = "4",
doi = "10.1007/s11060-013-1056-z",
language = "English (US)",
volume = "112",
pages = "173--178",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Interlaboratory comparison of IDH mutation detection

AU - Van Den Bent, Martin J.

AU - Hartmann, C.

AU - Preusser, Matthias

AU - Ströbel, Thomas

AU - Dubbink, Hendrikus J.

AU - Kros, Johan M.

AU - Von Deimling, Andreas

AU - Boisselier, Blandine

AU - Sanson, Marc

AU - Halling, Kevin C.

AU - Diefes, Kristin L.

AU - Aldape, Kenneth

AU - Giannini, Caterina

PY - 2013/4

Y1 - 2013/4

N2 - Isocitrate dehydrogenase (IDH) mutational testing is becoming increasingly important. For this, robust and reliable assays are needed. We tested the variation of results between six laboratories of testing for IDH mutations. Each laboratory received five unstained slides from 31 formalin-fixed paraffin-embedded (FFPE) glioma samples, and followed its own standard IDH diagnostic routine. All laboratories used immunohistochemistry (IHC) with an antibody against the most frequent IDH1 mutation (R132H) as a first step. Three laboratories then sequenced only IHC negative cases while the others sequenced all cases. Based on the overall analysis, 13 samples from 11 tumors had an R132H mutation and one tumor showed an R132G mutation. Results of IHC for IDH1 R132H mutations in all six laboratories were completely in agreement, and identified all R132H mutations. Upon sequencing the results of two laboratories deviated from those of the others. After a review of the entire diagnostic process, on repeat (blinded) testing one laboratory was completely in agreement with the overall result. A change in technique did only partially improve the results in the other laboratory. IHC for the IDH1 R132H mutation is very reliable and consistent across laboratories. IDH sequencing procedures yielded inconsistent results in 2 out of 6 laboratories. Quality assurance is pivotal before IDH testing is made part of clinical management of patients.

AB - Isocitrate dehydrogenase (IDH) mutational testing is becoming increasingly important. For this, robust and reliable assays are needed. We tested the variation of results between six laboratories of testing for IDH mutations. Each laboratory received five unstained slides from 31 formalin-fixed paraffin-embedded (FFPE) glioma samples, and followed its own standard IDH diagnostic routine. All laboratories used immunohistochemistry (IHC) with an antibody against the most frequent IDH1 mutation (R132H) as a first step. Three laboratories then sequenced only IHC negative cases while the others sequenced all cases. Based on the overall analysis, 13 samples from 11 tumors had an R132H mutation and one tumor showed an R132G mutation. Results of IHC for IDH1 R132H mutations in all six laboratories were completely in agreement, and identified all R132H mutations. Upon sequencing the results of two laboratories deviated from those of the others. After a review of the entire diagnostic process, on repeat (blinded) testing one laboratory was completely in agreement with the overall result. A change in technique did only partially improve the results in the other laboratory. IHC for the IDH1 R132H mutation is very reliable and consistent across laboratories. IDH sequencing procedures yielded inconsistent results in 2 out of 6 laboratories. Quality assurance is pivotal before IDH testing is made part of clinical management of patients.

KW - IDH1

KW - Immunohistochemistry

KW - Interlaboratory comparison

KW - Sequencing

UR - http://www.scopus.com/inward/record.url?scp=84877825900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877825900&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1056-z

DO - 10.1007/s11060-013-1056-z

M3 - Article

C2 - 23358936

AN - SCOPUS:84877825900

VL - 112

SP - 173

EP - 178

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -